<DOC>
	<DOCNO>NCT02344199</DOCNO>
	<brief_summary>Beta-blockers administer patient heart failure stage II IV accord NYHA.Beta-blockers reduce mortality hospitalization improve operational phase category patient heart failure . Since beta-blockers , carvedilol , metoprolol , bisoprolol recently nevimpololi show benefit , evidence provide . Eplerenone indicate , addition conventional therapy , reduce risk cardiovascular mortality morbidity stable patient leave ventricular dysfunction ( LVEF ≤ 40 % ) clinically proven heart failure recent myocardial infarction .</brief_summary>
	<brief_title>Eplerenone Heart Failure Treatment</brief_title>
	<detailed_description>Heart Failure ( HF ) As heart failure define complex clinical syndrome result structural functional cardiac disorder affect ability ventricle accept eject blood . Its incidence increase recent year Western world . It estimate 6 % - 10 % population 65 suffers heart failure . The clinical picture heart failure shortness breath , fatigue tolerance restriction fluid retention lead pulmonary congestion peripheral edema . These symptom sign require appear patient . Some patient simply reduce exercise tolerance , others dominate swell report dyspnea fatigue . For diagnosis heart failure necessary apart existence symptom objective confirmation cardiac dysfunction , preferably echocardiography , specialize less available method , magnetic resonance image heart radionuclide ventriculography . Coronary heart disease nowadays dominant cause heart failure , 65-70 % patient heart failure suffer coronary disease . The cardiomyopathy especially dilate , cause heart failure 20 % case . The myocarditis , hyperthyroidism abuse ethanol , responsible significant number patient type distend heart failure . Hypertension valvular dominate past , occupy small percentage today heart failure cause . The heart failure divide right left , depend whether predominant symptom result congestion systemic pulmonary vein , respectively . Moreover , heart failure separate systolic diastolic depend whether systolic diastolic performance leave ventricle affect . In patient systolic heart failure diastolic dysfunction coexist . However , 30 % patient heart failure pure diastolic dysfunction . For diagnosis heart failure diastolic dysfunction criterion require : 1 . In presence sign symptom heart failure 2. ejection fraction leave ventricle &gt; 45 % 3. presence one three type abnormal leave ventricular filling diastole ( relaxation extension , restrictive type ) . There four operating stage depend symptom patient heart failure , accord classification NYHA ( New York Heart Association ) . At operational stage I patient symptoms heart failure high level exercise , beyond ordinary . In stage II , symptom appear regular exercise level stage III small fatigue , stage IV symptom occur rest , patient unable look . Medication diet alter operate phase patient , without significant change occur ventricular performance . It particularly interesting little correlation symptom systolic leave ventricular performance express ejection fraction . Thus , patient low ejection fraction &lt; 25 % virtually asymptomatic , others slightly influence ejection fraction serious discomfort . Changes abdominal diatasimotitas pericardial voltage , valvular deficiency especially function right ventricle factor together systolic leave ventricular performance determine occurrence symptom heart failure patient . In heart failure function leave ventricle gradually worsen even absence new effect damaging agent . This famous remodeling ( Cardiac Remodeling ) leave ventricle , investigator dilatation , hypertrophy spherical shape . Thus , mechanical performance ventricle decrease , increase mitral insufficiency due distension mitral annulus , increase parietal stress . Ventricular remodel contribute continuous deterioration symptom , despite treatment . The activation neurohormonal system prove important factor cardiac remodel unfavorable development heart failure . Patients heart failure plasma level noradrenaline , angiotensin II , aldosterone , endothelin cytokine may act deleteriously structure function heart . The mobilization neurohormonal mechanism heart failure cause fluid retention sodium , peripheral vasoconstriction , myocardial fibrosis toxic effect myocardial cell , create vicious cycle deteriorate architecture performance fail heart . Ejection Fraction The relation stroke volume , extrude left ventricle start end diastole filling volume give measure contractile function leave ventricle . Each patient know cardiovascular disease subject assessment leave ventricular function measure ejection fraction . Several study demonstrate ejection fraction ( LVEF ) , measure ability heart eject blood aorta , exceed 40 % ( natural rate ^ 50 % ) increase dramatically postinfarction mortality . The ejection fraction reliable prognostic indicator calculate ultrasonography . The reduced ejection fraction associate increase risk life-threatening arrhythmia , heart failure death . A low ejection fraction , particularly myocardial infarction , strong indication administration beta-blockers , many study show administration drug significantly reduce cardiovascular mortality . Rationale study This study intend recruit within 6 month clinical practice Greek reality regard data administration eplerenone addition standard therapy include beta-blockers , reduce risk cardiovascular mortality morbidity stable patient dysfunction leave ventricle ( LVEF ≤ 40 % ) clinically proven heart failure recent myocardial infarction .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Eligible age study : &gt; 18 year Patients receive eprelenone accord standard clinical practice Patients heart failure ischemic / nonischemic etiology Patients receive standard therapy include betablockers , reduce risk cardiovascular mortality morbidity Stable patient Patients leave ventricular dysfunction ( LVEF ≤ 40 % ) Patients clinically proven heart failure recent myocardial infarction . Patients fully understood study protocol sign consent form Patients &lt; 18 year Hypersensitivity eplerenone excipients Patients serum potassium level &gt; 5,0 mmol / L start therapy Patients moderate severe renal impairment ( creatinine clearance &lt; 50 mL / min ) Patients severe hepatic impairment ( ChildPugh class C ) Patients take diuretic guard potassium loss strong inhibitor CYP3A4 ( eg itraconazole , ketoconazole , ritonavir , nelfinavir , clarithromycin , telithromycin nefazodone ) Patients fully understood study protocol sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>